IMVT
Immunovant, Inc.
A clinical-stage biopharmaceutical company developing experimental antibody medicines for autoimmune diseases, where the body's own defenses attack healthy tissue. Its drug candidates, like batoclimab, work by lowering the harmful antibodies that drive these conditions. Immunovant was founded in 2018 within the Roivant Sciences family and went public in 2019 through a merger. Its name blends "immuno," for immunology, with the "-vant" suffix that Roivant gives all its specialized subsidiaries.
CUSIP: 45258J102HealthcareUS2 holders
Total Value
$20.25M
Total Shares
1.18M
Net Share Change
-292.5K
Activity
1 selling
Investor
Value
Shares
Weight
Change
